CA1333163C - Methodes d'isolement de l'activateur tissulaire du plasminogene - Google Patents

Methodes d'isolement de l'activateur tissulaire du plasminogene

Info

Publication number: CA1333163C
Authority: CA; Canada
Prior art keywords: serum; medium; intact; fractionated; lysine
Prior art date: 1986-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000546345A

Other languages

English (en)

Inventor

Craig W. Rice

Michael John Morser

Peter Donner

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

C O D O N

Original Assignee

C O D O N

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-05

Filing date

1987-09-08

Publication date

1994-11-22

1986-09-05 Priority claimed from PCT/US1986/001831 external-priority patent/WO1987001389A1/fr

1987-09-08 Application filed by C O D O N filed Critical C O D O N

1994-11-22 Application granted granted Critical

1994-11-22 Publication of CA1333163C publication Critical patent/CA1333163C/fr

2011-11-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 66
108090000373 Tissue Plasminogen Activator Proteins 0.000 title claims description 313
102000003978 Tissue Plasminogen Activator Human genes 0.000 title claims description 313
229960000187 tissue plasminogen activator Drugs 0.000 title claims description 309
238000011084 recovery Methods 0.000 title description 28
108090000623 proteins and genes Proteins 0.000 claims abstract description 43
102000004169 proteins and genes Human genes 0.000 claims abstract description 43
239000000758 substrate Substances 0.000 claims abstract description 41
239000007788 liquid Substances 0.000 claims abstract description 25
210000002966 serum Anatomy 0.000 claims description 68
239000002609 medium Substances 0.000 claims description 60
239000013522 chelant Substances 0.000 claims description 32
210000004027 cell Anatomy 0.000 claims description 31
102000013566 Plasminogen Human genes 0.000 claims description 23
108010051456 Plasminogen Proteins 0.000 claims description 23
239000004472 Lysine Substances 0.000 claims description 19
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 10
229910052751 metal Inorganic materials 0.000 claims description 10
239000002184 metal Substances 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 8
239000011159 matrix material Substances 0.000 claims description 6
239000012679 serum free medium Substances 0.000 claims description 6
150000001768 cations Chemical class 0.000 claims description 5
230000002797 proteolythic effect Effects 0.000 claims description 5
210000004748 cultured cell Anatomy 0.000 claims description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
239000002797 plasminogen activator inhibitor Substances 0.000 claims description 2
150000001875 compounds Chemical class 0.000 abstract description 23
239000000203 mixture Substances 0.000 abstract description 23
239000008194 pharmaceutical composition Substances 0.000 abstract description 7
238000000926 separation method Methods 0.000 abstract description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 97
239000011780 sodium chloride Substances 0.000 description 48
229920005989 resin Polymers 0.000 description 47
239000011347 resin Substances 0.000 description 47
229920002684 Sepharose Polymers 0.000 description 40
230000000694 effects Effects 0.000 description 39
235000018102 proteins Nutrition 0.000 description 36
239000011701 zinc Substances 0.000 description 33
239000000243 solution Substances 0.000 description 30
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 23
239000000872 buffer Substances 0.000 description 23
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 23
229920000053 polysorbate 80 Polymers 0.000 description 23
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 22
229920001993 poloxamer 188 Polymers 0.000 description 22
108010039627 Aprotinin Proteins 0.000 description 20
102000009123 Fibrin Human genes 0.000 description 20
108010073385 Fibrin Proteins 0.000 description 20
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 20
229960004405 aprotinin Drugs 0.000 description 20
229950003499 fibrin Drugs 0.000 description 20
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 20
108090000790 Enzymes Proteins 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 18
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
102000001938 Plasminogen Activators Human genes 0.000 description 16
108010001014 Plasminogen Activators Proteins 0.000 description 16
229940127126 plasminogen activator Drugs 0.000 description 16
230000001225 therapeutic effect Effects 0.000 description 16
238000010828 elution Methods 0.000 description 15
238000004587 chromatography analysis Methods 0.000 description 13
235000018977 lysine Nutrition 0.000 description 12
108010088842 Fibrinolysin Proteins 0.000 description 10
230000001143 conditioned effect Effects 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 9
239000003446 ligand Substances 0.000 description 9
229940012957 plasmin Drugs 0.000 description 9
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
239000003599 detergent Substances 0.000 description 8
239000012634 fragment Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000005406 washing Methods 0.000 description 8
102000008946 Fibrinogen Human genes 0.000 description 7
108010049003 Fibrinogen Proteins 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
239000003636 conditioned culture medium Substances 0.000 description 7
229940012952 fibrinogen Drugs 0.000 description 7
239000000463 material Substances 0.000 description 7
239000012528 membrane Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000001179 sorption measurement Methods 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
208000007536 Thrombosis Diseases 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000012141 concentrate Substances 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
201000001441 melanoma Diseases 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
239000000047 product Substances 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000011734 sodium Substances 0.000 description 6
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
235000013922 glutamic acid Nutrition 0.000 description 5
239000004220 glutamic acid Substances 0.000 description 5
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 5
239000003104 tissue culture media Substances 0.000 description 5
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
239000003480 eluent Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000002537 thrombolytic effect Effects 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
235000019766 L-Lysine Nutrition 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000012190 activator Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000020764 fibrinolysis Effects 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
239000013587 production medium Substances 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000013019 agitation Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
238000007865 diluting Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
229960004198 guanidine Drugs 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
102000047823 human PLAT Human genes 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000004017 serum-free culture medium Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
-1 tranexamic acid Chemical class 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
CAJXYXPLLJDEOB-SLFFLAALSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-n-(4-nitrophenyl)hexanamide Chemical compound CC(C)[C@@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 CAJXYXPLLJDEOB-SLFFLAALSA-N 0.000 description 1
WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
UKWNUMRFXRKSTE-UHFFFAOYSA-N 5-aminoheptanoic acid Chemical compound CCC(N)CCCC(O)=O UKWNUMRFXRKSTE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
GIVWETPOBCRTND-DCAQKATOSA-N Arg-Gln-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GIVWETPOBCRTND-DCAQKATOSA-N 0.000 description 1
IWLZBRTUIVXZJD-OLHMAJIHSA-N Asp-Thr-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O IWLZBRTUIVXZJD-OLHMAJIHSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010011084 Coronary artery embolism Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
ZZYYVZYAZCMNPG-RQJHMYQMSA-N D-lysopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCC[NH3+] ZZYYVZYAZCMNPG-RQJHMYQMSA-N 0.000 description 1
IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
CXFUMJQFZVCETK-FXQIFTODSA-N Gln-Cys-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O CXFUMJQFZVCETK-FXQIFTODSA-N 0.000 description 1
PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 1
CMBXOSFZCFGDLE-IHRRRGAJSA-N Gln-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O CMBXOSFZCFGDLE-IHRRRGAJSA-N 0.000 description 1
XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
BGZIJZJBXRVBGJ-SXTJYALSSA-N Ile-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N BGZIJZJBXRVBGJ-SXTJYALSSA-N 0.000 description 1
BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical compound NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 description 1
239000012741 Laemmli sample buffer Substances 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 1
ZZYYVZYAZCMNPG-UHFFFAOYSA-N Lysopine Natural products OC(=O)C(C)NC(C(O)=O)CCCCN ZZYYVZYAZCMNPG-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
KLFPZIUIXZNEKY-DCAQKATOSA-N Met-Gln-Met Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O KLFPZIUIXZNEKY-DCAQKATOSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000047703 Nonion Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
108010065081 Phosphorylase b Proteins 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
OSXNCKRGMSHWSQ-ACRUOGEOSA-N Tyr-His-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSXNCKRGMSHWSQ-ACRUOGEOSA-N 0.000 description 1
YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical class NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
229940023913 cation exchange resins Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
238000001514 detection method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
238000002386 leaching Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
238000011027 product recovery Methods 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000011012 sanitization Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
229960000401 tranexamic acid Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
238000007805 zymography Methods 0.000 description 1

Landscapes

Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000546345A 1986-09-05 1987-09-08 Methodes d'isolement de l'activateur tissulaire du plasminogene Expired - Fee Related CA1333163C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US1986/001831 WO1987001389A1 (fr)	1985-09-06	1986-09-05	Procedes de recuperation d'un activateur de plasminogene des tissus
WOPCT/US86/01831		1986-09-05

Publications (1)

Publication Number	Publication Date
CA1333163C true CA1333163C (fr)	1994-11-22

Family

ID=22195626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000546345A Expired - Fee Related CA1333163C (fr)	1986-09-05	1987-09-08	Methodes d'isolement de l'activateur tissulaire du plasminogene

Country Status (1)

Country	Link
CA (1)	CA1333163C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111500563A (zh) *	2020-05-08	2020-08-07	华兰生物工程重庆有限公司	一种从人血浆中纯化人凝血因子ⅶ的方法

1987
- 1987-09-08 CA CA000546345A patent/CA1333163C/fr not_active Expired - Fee Related

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111500563A (zh) *	2020-05-08	2020-08-07	华兰生物工程重庆有限公司	一种从人血浆中纯化人凝血因子ⅶ的方法
CN111500563B (zh) *	2020-05-08	2023-10-13	华兰生物工程重庆有限公司	一种从人血浆中纯化人凝血因子ⅶ的方法

Legal Events

Date	Code	Title	Description
1997-11-24	MKLA	Lapsed

Publication	Publication Date	Title
US4960702A (en)	1990-10-02	Methods for recovery of tissue plasminogen activator
US4752603A (en)	1988-06-21	Plasminogen activator and pharmaceutical composition having thrombolytic activity
US4902623A (en)	1990-02-20	Plasminogen activator
Chibber et al.	1974	[48] Plasminogen
AU606582B2 (en)	1991-02-14	Methods for the recovery of tissue plasminogen activator
JP2010540432A (ja)	2010-12-24	ヒト組織型プラスミノーゲンアクチベータの精製方法
FI96211B (fi)	1996-02-15	Menetelmä yksisäikeisen kudosplasminogeeniaktivaattorin (tPA) ja kaksisäikeisen tPA:n puhdistamiseksi ja eristämiseksi
US6001355A (en)	1999-12-14	Pro-tPA for the treatment of thrombosis, embolism and related conditions
CA1333163C (fr)	1994-11-22	Methodes d'isolement de l'activateur tissulaire du plasminogene
Bansal et al.	2006	Recovery of urokinase from integrated mammalian cell culture cryogel bioreactor and purification of the enzyme using p‐aminobenzamidine affinity chromatography
EP1015568B1 (fr)	2003-02-26	PROCEDE DE PRODUCTION DE rDSPA Alpha1
Soeda et al.	1986	Rapid and high-yield purification of porcine heart tissue-type plasminogen activator by heparin-sepharose choromatography
EP0276328B1 (fr)	1993-03-10	Procede pour separer l'un de l'autre un tPA Humain Mono-Brin et un tPA Humain Double-Brin
JPH0223158B2 (fr)	1990-05-23
US5139939A (en)	1992-08-18	Process for the production of human tissue plasminogen activator and cell strain useful therefor
US5723122A (en)	1998-03-03	Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
EP0275282A1 (fr)	1988-07-27	Procede de purification d'un activateur de plasminogene
CA1335186C (fr)	1995-04-11	Methode de purification de l'activateur tissulaire du plasminogene
JP2714817B2 (ja)	1998-02-16	ウロキナーゼ前駆体の製造方法
JPS63317082A (ja)	1988-12-26	ｔＰＡの精製
KR20000029755A (ko)	2000-05-25	트롬빈에의해활성화될수있는플라스미노겐활성화제
WO1993014199A1 (fr)	1993-07-22	Procede catalyse par pump-1 de production d'activateur du plasminogene de type urokinase de faible masse moleculaire
OGISO et al.	1987	Measurement of human urokinase activity in plasma by using mono-specific antibody-conjugated paper disk
MXPA99000966A (en)	1999-09-20	Plasminogen activator capable of being activated by thrombin
EP0281579A1 (fr)	1988-09-14	Co-facteur de prourokinase